Drug intelligence / Profile preview

SKM-201

Development stage: Preclinical
Lead developer: Skymab Biotherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SKM-201 is an antibody-drug conjugate (ADC) developed by Skymab Biotherapeutics. It is currently in preclinical development for the treatment of neoplasms, with a primary focus on solid tumors. As an ADC, SKM-201 combines the targeting specificity of a monoclonal antibody with the cytotoxic potency of a linked drug payload, aiming to selectively deliver chemotherapy to cancer cells while minimizing effects on healthy tissue. Detailed information about its specific molecular target and payload has not been disclosed publicly[1].

Targets

CCR10 (C-C chemokine receptor type 10)

Beyond the preview

Go deeper on SKM-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKM-201.

Explore the full profile